Development asset linked to Eastern Hepatobiliary Surgery in public FDA and regional records.
pharma · Gastric Cancer
Eastern Hepatobiliary Surgery
Eastern Hepatobiliary Surgery Hospital
Eastern Hepatobiliary Surgery drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 4
- Patents
- 0
Eastern Hepatobiliary Surgery pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Eastern Hepatobiliary Surgery drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
tegafur
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Eastern Hepatobiliary Surgery's portfolio. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Eastern Hepatobiliary Surgery in public FDA and regional records.
-
Development asset linked to Eastern Hepatobiliary Surgery in public FDA and regional records.